Our findings of dasatinib-insensitive CD34+ cells (Fig. 5c and Supplementary Fig. 4), in the CML patients sampled point to incomplete inhibition of BCR-ABL gene, or downstream phosphoprotein target activity as an underlying mechanism in CML persistence. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.